+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bispecific Antibodies"

Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • August 2025
  • 224 Pages
  • Global
From
Protein Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Protein Therapeutics - Global Strategic Business Report

  • Report
  • August 2025
  • 181 Pages
  • Global
From
Combination Antibody Therapy - Global Strategic Business Report - Product Thumbnail Image

Combination Antibody Therapy - Global Strategic Business Report

  • Report
  • August 2025
  • 196 Pages
  • Global
From
Antibody Production - Global Strategic Business Report - Product Thumbnail Image

Antibody Production - Global Strategic Business Report

  • Report
  • August 2025
  • 392 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 193 Pages
  • Global
From
Monoclonal Antibodies - Global Strategic Business Report - Product Thumbnail Image

Monoclonal Antibodies - Global Strategic Business Report

  • Report
  • August 2025
  • 213 Pages
  • Global
From
Autoimmune Monoclonal Antibody Global Market Report 2025 - Product Thumbnail Image

Autoimmune Monoclonal Antibody Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Cancer Cachexia - Pipeline Insight, 2025 - Product Thumbnail Image

Cancer Cachexia - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 80 Pages
  • Global
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 280 Pages
  • Global
From
Esophageal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Esophageal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 280 Pages
  • Global
From
Nasopharyngeal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Nasopharyngeal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Advanced Merkel Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Merkel Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Biliary Tumor - Pipeline Insight, 2025 - Product Thumbnail Image

Biliary Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Anti-CD40 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD40 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Acquired Hemophilia A - Pipeline Insight, 2025 - Product Thumbnail Image

Acquired Hemophilia A - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 50 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • March 2025
  • 450 Pages
  • Global
From
From
Bioprocessing Analytics - Global Strategic Business Report - Product Thumbnail Image

Bioprocessing Analytics - Global Strategic Business Report

  • Report
  • August 2025
  • 371 Pages
  • Global
From
From
Loading Indicator

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases. Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments. The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more